Theraclion S.A.
TCLIF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -8.1% | 141.8% | -47.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -353.5% | -377.7% | -708.4% | -49.3% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | -$0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | -$0 | $0 |
| Operating Expenses | -$0 | $0 | -$0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -349.8% | -270.9% | -706.6% | 3.1% |
| Other Income/Exp. Net | $0 | -$0 | $0 | -$0 |
| Pre-Tax Income | $0 | -$0 | -$0 | -$0 |
| Tax Expense | -$0 | -$0 | -$0 | -$0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -304.3% | -317.6% | -534.6% | -142.5% |
| EPS | -0.065 | -0.073 | -0.052 | -0.026 |
| % Growth | 11.9% | -41.6% | -97.3% | – |
| EPS Diluted | -0.065 | -0.073 | -0.052 | -0.026 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | -$0 | $0 | -$0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -323.3% | -270.9% | -627.5% | -193.6% |